Introduction
Joint wear can affect joint health, causing pain and limiting movement, and cartilage has a very limited ability to heal itself. This article explains the ChondroFiller injection — a simple, non-surgical procedure — with realistic expectations throughout.
What Is the ChondroFiller Injection?
ChondroFiller is a CE-marked (Class III medical device) acellular type I collagen hydrogel scaffold, manufactured by Meidrix Biomedicals in Germany and imported into the UK under prescription. When delivered as a non-surgical outpatient procedure, it is given as an ultrasound-guided injection directly into the joint. The liquid gel may settle over worn cartilage surfaces, adding a supportive collagen layer that helps cushion the joint and reduce grinding. It is cell-free — it does not itself contain stem cells — but it recruits the patient's own progenitor cells to support repair.
Because it is acellular and self-gelling (the scaffold solidifies within a few minutes of delivery), the procedure needs no incision and no removal of cartilage tissue. Evidence from published clinical series suggests meaningful improvements in pain and function in suitable patients, though outcomes vary and the injection is not a cure for arthritis.
Is It Complicated?
From a patient's perspective, the injection involves straightforward preparation, a short appointment and simple recovery. Ultrasound guidance allows a clinician to direct a fine needle precisely to the joint surface without any incision. There is no requirement for theatre, no general anaesthetic and no overnight stay. Most patients can return to gentle daily activities relatively quickly, though full recovery of the joint depends on the underlying condition being treated.
Staying in Place — Without Stitches
A practical feature of ChondroFiller is how the gel adheres once delivered. The collagen scaffold forms stable bonds with the biological environment of the defect, remaining securely in place without the need for sutures or fibrin glue. This self-adherent property simplifies the procedure considerably compared with approaches that require fixation.
It is important to be clear about what the injection is and what it is not. ChondroFiller is collagen-based with biological potential — it provides a scaffold that the body may use to support cartilage repair over time — but it is best understood as a supportive, joint-preserving intervention, not a cure or reversal of osteoarthritis. Benefits vary between patients, and a specialist assessment is needed to establish whether it is appropriate for a given joint and degree of wear.
How the ChondroFiller Injection Differs from Surgical Options
ChondroFiller can be delivered in two ways: as a non-surgical injection in an outpatient setting, or as part of a keyhole surgical procedure for larger or more complex lesions. This article focuses on the injection pathway. Where a defect is larger, involves a major load-bearing joint, or requires additional biological support, a specialist may recommend the Liquid Cartilage protocol instead — a keyhole (arthroscopic) surgical procedure that delivers the ChondroFiller scaffold together with biological adjuncts and, where indicated, the patient's own mesenchymal stem cells. That is a distinct, surgical pathway and is covered separately.
The ChondroFiller injection as a standalone non-surgical procedure is suited to accessible lesions and joints where the defect size and patient profile support a non-operative approach.
Published Evidence
In published clinical series, patients receiving ChondroFiller have shown consistent improvements in joint function scores over 12 to 36 months. In knee studies, International Knee Documentation Committee (IKDC) scores have improved by approximately 30 points. In hip applications, modified Harris Hip Score (mHHS) improvements of more than 30 points have been reported. Imaging using MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) scores in published series has reached around 80 and above, suggesting good-quality tissue regeneration and defect fill.
A 2023 study by Corain and colleagues examined ChondroFiller Liquid in trapeziometacarpal osteoarthritis and reported significant pain reduction and functional improvement in that smaller joint. Across more than 19,000 units sold since 2013, the device has shown a strong safety record, with no serious incidents reported in the manufacturer's clinical evaluation data.
Conclusion
The ChondroFiller injection combines a simple, ultrasound-guided technique with a favourable safety profile — no incision, no cartilage removal, and a short appointment — and may help support joint preservation in suitable patients. It is not surgery, it is not a cure, and a careful individual assessment is essential before proceeding. At the London Cartilage Clinic, assessments are carried out to determine whether the ChondroFiller injection, or a more involved surgical approach such as Liquid Cartilage, is the right option for you. If you are considering this treatment, a consultation with a qualified specialist is the recommended first step.
References
Corain, M., Zanotti, F., Giardini, M., Gasperotti, L., Invernizzi, E., Biasi, V., & Lavagnolo, U. (2023). The use of an acellular collagen matrix ChondroFiller Liquid for trapeziometacarpal osteoarthritis. Cartilage.
Frequently Asked Questions
- It is a non-surgical, ultrasound-guided collagen injection — no incision and no cartilage removal — that may add a supportive, cushioning layer over worn joint surfaces by providing a scaffold the body can use for repair. It is not a corticosteroid, not a filler, and not a cure; it is a CE-marked Class III medical device with a biological mechanism of action.
- Clinical series include the knee, hip, ankle and smaller joints such as the trapeziometacarpal joint of the thumb. Suitability depends on the size and grade of the defect, the degree of underlying wear, and the individual patient's health profile. A specialist assessment is needed to determine whether the injection is appropriate for a particular joint.
- It is straightforward from the patient's perspective — a short outpatient appointment, ultrasound-guided needle placement, no incision, and no general anaesthetic. Recovery is simple, though the time before the joint fully benefits depends on the extent of the underlying condition.
- ChondroFiller is a CE-marked collagen scaffold that can be delivered either as a non-surgical injection or placed surgically. The ChondroFiller injection is an outpatient procedure with no theatre and no anaesthetic, suited to accessible lesions. Liquid Cartilage is a distinct keyhole surgical protocol — developed at the London Cartilage Clinic — that delivers ChondroFiller together with biological adjuncts and, where indicated, the patient's own stem cells. Liquid Cartilage involves theatre, anaesthetic and a structured recovery; it is appropriate for larger or more complex lesions.
- Published evidence suggests meaningful improvements in pain and function over 12 to 36 months in suitable patients, but outcomes vary. The injection supports the joint's own repair environment rather than guaranteeing cartilage regrowth or reversing arthritis. A specialist will discuss realistic expectations based on your imaging, symptom profile, and overall joint health before recommending this treatment.
Where to go from here
A few next steps tailored to what you have just read.
Legal & Medical Disclaimer
This article is written by an independent contributor and reflects their own views and experience, not necessarily those of London Cartilage Clinic. It is provided for general information and education only and does not constitute medical advice, diagnosis, or treatment.
Always seek personalised advice from a qualified healthcare professional before making decisions about your health. London Cartilage Clinic accepts no responsibility for errors, omissions, third-party content, or any loss, damage, or injury arising from reliance on this material.
If you believe this article contains inaccurate or infringing content, please contact us at [email protected].
